NCT06391918View on ClinicalTrials.gov

Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

March 4, 2024

Primary Completion Date

March 1, 2027

Study Completion Date

March 1, 2028

Conditions
Solid Tumor, Adult
Interventions
BIOLOGICAL

GEN2 + Valganciclovir

Gene therapy vector product

Trial Locations (6)

22031

RECRUITING

NEXT Oncology, Fairfax

37203

RECRUITING

SCRI Oncology Partners, Nashville

46202

RECRUITING

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

90033

RECRUITING

University of Southern California-Keck School of Medicine, Los Angeles

90095

RECRUITING

UCLA Hematology-Oncology, Los Angeles

91010

RECRUITING

City of Hope, Duarte

Sponsors

Lead Sponsor

GenVivo, Inc.
All Listed Sponsors
lead

GenVivo, Inc.

INDUSTRY

NCT06391918 - Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter